Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

0
48
Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation for IBI343 as monotherapy for the treatment of claudin18.2-positive advanced gastric/gastro-esophageal junction adenocarcinoma patients who have progressed after at least 2 lines of prior systematic treatments.
[Innovent Biologics, Inc.]
Press Release